A look into TScan Therapeutics Inc. (TCRX)’s deeper side

TScan Therapeutics Inc. (NASDAQ: TCRX) stock fell -0.95% on Monday to $2.08 against a previous-day closing price of $2.10. With 6.07 million shares changed hands, the volume of the stock remained heavier than its average volume of 26680.0 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.6700 whereas the lowest price it dropped to was $1.9500. The 52-week range on TCRX shows that it touched its highest point at $5.60 and its lowest point at $1.45 during that stretch. It currently has a 1-year price target of $14.00.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TCRX was down-trending over the past week, with a drop of -5.45%, but this was up by 30.00% over a month. Three-month performance dropped to -35.00% while six-month performance fell -37.91%. The stock lost -55.93% in the past year, while it has gained 34.19% so far this year. A look at the trailing 12-month EPS for TCRX yields -2.58 with Next year EPS estimates of -3.08. For the next quarter, that number is -0.70. This implies an EPS growth rate of -86.10% for this year and -10.80% for next year.

Float and Shares Shorts:

At present, 24.07 million TCRX shares are outstanding with a float of 17.61 million shares on hand for trading. On Oct 13, 2022, short shares totaled 55680.0, which was 0.23% higher than short shares on Sep 14, 2022. In addition to Mr. David P. Southwell as the firm’s Pres, CEO & Director, Mr. Brian Michael Silver J.D. serves as its Sr. VP, CFO & Treasurer.


Institutional Ownership:

Through their ownership of 58.53% of TCRX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 26.19% of TCRX, in contrast to 16.26% held by mutual funds. Shares owned by individuals account for 12.09%. As the largest shareholder in TCRX with 14.71% of the stake, Baker Bros. Advisors LP holds 2,784,792 shares worth 2,784,792. A second-largest stockholder of TCRX, BlackRock Advisors LLC, holds 1,436,451 shares, controlling over 7.59% of the firm’s shares. DC Investments Management LLC is the third largest shareholder in TCRX, holding 665,563 shares or 3.52% stake. With a 4.52% stake in TCRX, the BlackRock Health Sciences Trust I is the largest stakeholder. A total of 855,317 shares are owned by the mutual fund manager. The BlackRock Health Sciences Opportu, which owns about 2.91% of TCRX stock, is the second-largest Mutual Fund holder. It holds 551,194 shares valued at 0.85 million. Vanguard Total Stock Market Index holds 1.17% of the stake in TCRX, owning 220,934 shares worth 0.34 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TCRX since 5 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TCRX analysts setting a high price target of $21.00 and a low target of $6.00, the average target price over the next 12 months is $14.00. Based on these targets, TCRX could surge 909.62% to reach the target high and rise by 188.46% to reach the target low. Reaching the average price target will result in a growth of 573.08% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. TCRX will report FY 2022 earnings on 03/06/2024. Analysts have provided yearly estimates in a range of -$2.61 being high and -$3.20 being low. For TCRX, this leads to a yearly average estimate of -$2.76. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. TScan Therapeutics Inc. surprised analysts by $0.06 when it reported -$0.67 EPS against a consensus estimate of -$0.73. The surprise factor in the prior quarter was $0.11. Based on analyst estimates, the high estimate for the next quarter is -$0.63 and the low estimate is -$0.81. The average estimate for the next quarter is thus -$0.72.

Summary of Insider Activity:

Insiders traded TCRX stock several times over the past three months with 2 Buys and 0 Sells. In these transactions, 6,000 shares were bought while 0 shares were sold. The number of buy transactions has increased to 13 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 1,405,792 while 0 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *